



## (51) International Patent Classification:

A61K 31/713 (2006.01) C12N 15/113 (2010.01)

## (21) International Application Number:

PCT/US2022/023813

## (22) International Filing Date:

07 April 2022 (07.04.2022)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

|            |                            |    |
|------------|----------------------------|----|
| 63/172,301 | 08 April 2021 (08.04.2021) | US |
| 63/322,603 | 22 March 2022 (22.03.2022) | US |

(71) Applicant: **ARROWHEAD PHARMACEUTICALS, INC.** [US/US]; 177 East Colorado Boulevard, Suite 700, Pasadena, CA 91105 (US).

(72) Inventors: **NICHOLAS, Anthony**; 5247 W. Netherwood Road, Oregon, WI 53575 (US). **PEI, Tao**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **BUSH, Erik, W.**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **KASAHARA, David, Itiro**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US).

**SCHIENEBECK, Casi, M.**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US).

(74) Agent: **TEIGEN, Robert**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: RNAI AGENTS FOR INHIBITING EXPRESSION OF RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS, COMPOSITIONS THEREOF, AND METHODS OF USE




FIG. 1

(57) Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed, herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, *in vivo*, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

From the INTERNATIONAL BUREAU

**PCT**NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

To:

TEIGEN, Robert  
Arrowhead Pharmaceuticals, Inc.  
502 S. Rosa Road  
Madison, WI 53719  
ÉTATS-UNIS D'AMÉRIQUEDate of mailing (day/month/year)  
27 September 2023 (27.09.2023)Applicant's or agent's file reference  
30691-WO**IMPORTANT NOTIFICATION**International application No.  
PCT/US2022/023813International filing date (day/month/year)  
07 April 2022 (07.04.2022)

1. The following indications appeared on record concerning:

☐ the applicant ☒ the inventor ☐ the agent ☐ the common representative

Name and Address

PEI, Tao  
Arrowhead Pharmaceuticals, Inc.  
502 S. Rosa Road  
Madison, WI 53719  
UNITED STATES OF AMERICA

State of Nationality

State of Residence

Telephone No.

Facsimile No.

E-mail address

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

State of Nationality

State of Residence

Telephone No.

Facsimile No.

E-mail address

☐ Notifications by e-mail authorized

3. Further observations, if necessary:

The person identified in Box 1 has been deleted from the records.

4. A copy of this notification has been sent to:

☒ the receiving Office☐ the International Searching Authority☐ the Authority(ies) specified for supplementary search☐ the International Preliminary Examining Authority☒ the designated Offices concerned☐ the elected Offices concerned☐ other:The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

Zhang Zhanchao

e-mail pct.team2@wipo.int

Telephone No. +41 22 338 74 02